Open AccessPROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION
Author(s) -
А. В. Рудакова,
Д. А. Гусев,
А. Н. Усков,
Л. Н. Коновалова,
Yu. V. Lobzin
Publication year - 2017
Publication title -
žurnal infektologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.185
H-Index - 5
eISSN - 2499-9865
pISSN - 2072-6732
DOI - 10.22625/2072-6732-2017-9-1-100-103
Subject(s) - cirrhosis , medicine , protease inhibitor (pharmacology) , gastroenterology , genotype , hepatitis c virus , virology , protease , hepatitis c , virus , viral load , biology , enzyme , antiretroviral therapy , biochemistry , gene